Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 11 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

45%

5 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 3
3(27.3%)
Phase 1
3(27.3%)
Phase 4
2(18.2%)
N/A
2(18.2%)
Phase 2
1(9.1%)
11Total
Phase 3(3)
Phase 1(3)
Phase 4(2)
N/A(2)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials
NCT07117669Phase 1Recruiting

Study of ENP-501 in Peanut-Allergic and Non-Allergic Participants

Role: collaborator

NCT07328542Phase 4Not Yet Recruiting

Ambulatory Blood Pressure Monitoring (ABPM) Study in Hypogonadal Men

Role: collaborator

NCT07146217Phase 2Not Yet Recruiting

Pharmacokinetic and Safety Study of Metronidazole Oral Suspension in Pediatric Patients With Anaerobic Bacterial Infection

Role: collaborator

NCT06234098Phase 1Recruiting

Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors

Role: collaborator

NCT05689333Not ApplicableCompleted

A Study to Evaluate the Safety and Performance of the Vista Probe for Vitrectomy Surgery

Role: collaborator

NCT05949697Not ApplicableCompleted

A Prospective Study of the Dry Eye Drink That Evaluates Hydration and Subject's Assessment on Eye Dryness

Role: collaborator

NCT06132035Phase 1Recruiting

Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration

Role: collaborator

NCT05322070Phase 4Active Not Recruiting

Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis

Role: collaborator

NCT05078827Phase 3Completed

Therapeutic Equivalence of Fluorouracil Cream, 5% Compared With Fluorouracil 5% Topical Cream of MylanPharmaceuticals Inc., U.S.A in the Treatment of Actinic Keratosis

Role: collaborator

NCT04890106Phase 3Completed

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN® In The Treatment of Chronic Open-Angle Glaucoma

Role: collaborator

NCT05401357Phase 3Recruiting

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.

Role: collaborator

All 11 trials loaded